• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Inspections, Compliance, Enforcement, and Criminal Investigations

  • Print
  • Share
  • E-mail

Notification of Stolen Actavis Products

 

FDA posts press releases and other notices from firms as a service to consumers, the media, and other interested parties.

 

Date Posted: November 2, 2011

 

On October 20, 2011, Actavis, Inc. reported to both local DEA and FDA officials that a truck, contracted by Actavis, carrying finished goods from our Elizabeth, New Jersey site to our distribution center in Kentucky was stolen.  The theft was immediately reported to the police.  At the present time, the subject product has not been located.

 

The product included in this shipment is as follows and represent full lot quantities :

 

Product                                                           Lot #               Expiry             # of Bottles

 

Gabapentin Tabs, USP 600 mg, 500 ct           117J11             8/31/2013        1,680

                                                                        118J11             9/30/2013        1,734

                                                                        206K11           9/30/2013        1,740

 

Alprazolam Tabs, USP 2 mg, 100 ct               001J11             8/31/2013        11,748

                                                                        002J11             8/31/2013        11,700

 

Oxycodone HCl Tabs, USP 15 mg, 100 ct     026J11             8/31/2013        33,696

                                                                        027J11             8/31/2013        34,008

 

 

Anyone who has information regarding this incident, or has received suspicious or unsolicited offers for the specified products after the date of the theft, is encouraged to contact the U.S. Food and Drug Administration (FDA) Office of Criminal Investigations at 1-800-551-3989 or to visit the OCI Web Site (http://www.fda.gov/OCI1). Additionally,  individuals are also encouraged to immediately contact the PA police, the OH police, or the DEA with information as to how you obtained such product.

While Actavis is confident that the batches in question posed no health risk to the consumer when they left our facility, Actavis urges any individuals who may be in possession of these batches of products to discontinue their use immediately and discard the product.  This recommendation is solely due to the fact that, once the theft occurred, the batches were no longer within Actavis control; therefore, we are unaware of the conditions under which the batches were stored. 

Healthcare professionals and  patients who may be in possession of these batches are encouraged to report any adverse events, side effects, or product quality problems related to the use of these batches to the FDA's MedWatch Safety Information and Adverse Event Reporting Program:

  • Complete and submit the report Online: www.fda.gov/MedWatch/report.htm1
  • Download form2 or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Alternatively, Healthcare professionals and patients may contact the Actavis U.S. Medical Affairs department toll-free at 1-800-432-8534.

Actavis’ top priority is the safety of its consumers and our commitment to the quality of our products.  We are aggressively pursuing the retrieval of these batches through full cooperation with the police as well as FDA (OCI) and DEA authorities.  We urge all consumers who are in possession of these batches to discontinue their use and follow the recommendations outlined above.

We thank you for your cooperation.